AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23915701 — intervention group
Group type: COMPARATOR
Intervention: Nasolabial flap
Number of subjects: 50
Study 22137512 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen tube (DLT)
Number of subjects: 75
Study 22137512 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 75
Study 22137512 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic endotracheal tube (ETT)
Number of subjects: 75
Study 19882577 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial microincision surgery
Number of subjects: 70
Study 19882577 — intervention group
Group type: COMPARATOR
Intervention: Coaxial small incision cataract surgery
Number of subjects: 70
Study 17078772 — intervention group
Group type: EXPERIMENTAL
Intervention: Water heated to 42 degrees C
Number of subjects: 11
Study 17078772 — intervention group
Group type: COMPARATOR
Intervention: Control water condition (temperature of the warmest limbs)
Number of subjects: 11
Study 17078772 — intervention group
Group type: COMPARATOR
Intervention: Control and warm water conditions
Number of subjects: 11
Study 15037490 — intervention group
Group type: COMPARATOR
Intervention: Light to moderate alcohol consumption (monthly, weekly, daily)
Number of subjects: 14125
Study 15037490 — intervention group
Group type: COMPARATOR
Intervention: Light to moderate alcohol consumption (monthly, weekly, daily) among men with systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg
Number of subjects: 14125
Study 15037490 — intervention group
Group type: COMPARATOR
Intervention: Moderate alcohol consumption
Number of subjects: 14125
Study 11709512 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 3.0 g twice daily
Number of subjects: 133
Study 11709512 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 1.5 g twice daily
Number of subjects: 133
Study 11709512 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine 0.5 g three times daily
Number of subjects: 133
Study 9473880 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual, focused breast‐feeding counselling
Number of subjects: 161
Study 9473880 — intervention group
Group type: COMPARATOR
Intervention: Routine advice for diarrhoea (Control)
Number of subjects: 161
Study 8561442 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil LI 120 mg 3 times a day
Number of subjects: 27
Study 8561442 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil LP 120 mg twice a day
Number of subjects: 27
Study 8561442 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 2122015 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (BSHGH) 0.1 mg/kg/day for 7 days
Number of subjects: 15
Study 2122015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2122015 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (BSHGH)
Number of subjects: 15
Study 225956 — intervention group
Group type: COMPARATOR
Intervention: Condition A (no external limb resistance)
Number of subjects: 12
Study 225956 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition B (3.1 Kg of premovement limb resistance)
Number of subjects: 12
Study 225956 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition C (9.8 Kg of premovement limb resistance)
Number of subjects: 12
Study 30269273 — intervention group
Group type: EXPERIMENTAL
Intervention: MR training in 3rd year preschoolers
Number of subjects: 2
Study 30269273 — intervention group
Group type: EXPERIMENTAL
Intervention: MR training in 1st year preschoolers
Number of subjects: 2
Study 30269273 — intervention group
Group type: COMPARATOR
Intervention: Comparison of training effects between 1st and 3rd year preschoolers
Number of subjects: 2
Study 31410893 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional denture (CD)
Number of subjects: 16
Study 31410893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed prosthesis (FP)
Number of subjects: 16
Study 31410893 — intervention group
Group type: EXPERIMENTAL
Intervention: Milled bar overdenture (MB)
Number of subjects: 16
Study 27596805 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital scanning (TRIOS Pod)
Number of subjects: 100
Study 27596805 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression (open tray with elastomer)
Number of subjects: 100
Study 27596805 — intervention group
Group type: COMPARATOR
Intervention: Digital scanning (TRIOS Pod) and Conventional impression (open tray with elastomer)
Number of subjects: 100
Study 26017816 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated-counseling website
Number of subjects: 98
Study 26017816 — intervention group
Group type: COMPARATOR
Intervention: Standard educational website
Number of subjects: 98
Study 24409806 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic, minimally invasive percutaneous plate osteosynthesis (MIPPO)
Number of subjects: 40
Study 24409806 — intervention group
Group type: COMPARATOR
Intervention: Modified plate fixation
Number of subjects: 40
Study 21834489 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg + atorvastatin 10 mg
Number of subjects: 93
Study 21834489 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 20 mg + placebo
Number of subjects: 93
Study 19858392 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 ibritumomab tiuxetan
Number of subjects: 414
Study 19858392 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 414
Study 16766978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutoplast-cancellous-chips (allograft)
Number of subjects: 90
Study 16766978 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone grafting (autologous)
Number of subjects: 90
Study 15729016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 50 mg/kg/day for 5 days
Number of subjects: 410
Study 15729016 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 40 mg/kg/day for 10 days
Number of subjects: 410
Study 11791125 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-containing polychemotherapy regimens
Number of subjects: 0
Study 11791125 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens containing epirubicin
Number of subjects: 0
Study 11791125 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin-taxane combinations
Number of subjects: 0
Study 11791125 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 9210991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 46
Study 9210991 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mastery therapy
Number of subjects: 46
Study 9210991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment depression
Number of subjects: 46
Study 9210991 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal problems at pre-treatment
Number of subjects: 46
Study 8353046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant interleukin-2 (rIL-2) at dose levels of 0.18, 0.6, 1.8, or 6 x 10(6) IU m-2 24 h-1; one patient treated with 3 x 10(6) IU m-2 24 h-1
Number of subjects: 13
Study 2297142 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with oral immunotherapy (Artemisia pollen extract) over a 50-day course, cumulative dose of 396,652 PNU
Number of subjects: 18
Study 2297142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 268377 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 APF tablet containing 1 mg fluoride
Number of subjects: 338
Study 268377 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 APF tablets (3 hours apart) each school day
Number of subjects: 338
Study 268377 — intervention group
Group type: COMPARATOR
Intervention: 1 placebo tablet
Number of subjects: 338
Study 31782864 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 41
Study 31782864 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 41
Study 31782864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diclofenac and tramadol
Number of subjects: 41
Study 31554360 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy with concurrent chemotherapy (Paclitaxel and Carboplatin)
Number of subjects: 29
Study 31554360 — intervention group
Group type: COMPARATOR
Intervention: HDR brachytherapy alone (standard of care arm)
Number of subjects: 29
Study 28292489 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based case management intervention
Number of subjects: 0
Study 25801652 — intervention group
Group type: EXPERIMENTAL
Intervention: TV005
Number of subjects: 168
Study 25801652 — intervention group
Group type: COMPARATOR
Intervention: TV003
Number of subjects: 168
Study 24288948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (1 g/day for 3 months)
Number of subjects: 40
Study 24288948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 months)
Number of subjects: 40
Study 21696241 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Impact intervention (n = 83)
Number of subjects: 166
Study 21696241 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (n = 83)
Number of subjects: 166
Study 19419355 — intervention group
Group type: EXPERIMENTAL
Intervention: NTS+MMG (Non-Technical Skills + Medical Management Group)
Number of subjects: 42
Study 19419355 — intervention group
Group type: COMPARATOR
Intervention: MMG (Medical Management Group)
Number of subjects: 42
Study 19419355 — intervention group
Group type: EXPERIMENTAL
Intervention: NTS+MMG
Number of subjects: 42
Study 19419355 — intervention group
Group type: COMPARATOR
Intervention: MMG
Number of subjects: 42
Study 16409457 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose antithrombin (AT)
Number of subjects: 563
Study 16409457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 15575918 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (1.5 mg/day)
Number of subjects: 0
Study 15575918 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (3 mg/day)
Number of subjects: 0
Study 15575918 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (control)
Number of subjects: 0
Study 15575918 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (TDM)
Number of subjects: 0
Study 15575918 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study 11728044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 592
Study 9457582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothenar fat pad flap modified closure
Number of subjects: 0
Study 9457582 — intervention group
Group type: COMPARATOR
Intervention: Standard closure
Number of subjects: 0
Study 8493292 — intervention group
Group type: EXPERIMENTAL
Intervention: Late Sleep Deprivation (LSD)
Number of subjects: 26
Study 8493292 — intervention group
Group type: COMPARATOR
Intervention: Early Sleep Deprivation (ESD)
Number of subjects: 26
Study 8493292 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 26
Study 8493292 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal levels (thyroid stimulating hormone, free triiodothyronine, prolactin, cortisol)
Number of subjects: 26
Study 2942050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin 10 mg
Number of subjects: 36
Study 2942050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin 20 mg
Number of subjects: 36
Study 2942050 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection of saline
Number of subjects: 36
Study 31228560 — intervention group
Group type: EXPERIMENTAL
Intervention: High School Transition Program (HSTP) intervention (n=247)
Number of subjects: 497
Study 31228560 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=233)
Number of subjects: 497
Study 29676972 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina air abrasion with 50‐μm alumina particles and Scotchbond Universal/RelyX Unicem 2 (Al-SU)
Number of subjects: 80
Study 29676972 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina air abrasion with 50‐μm alumina particles and Z‐Prime Plus/Duo‐link Universal (Al-ZP)
Number of subjects: 80
Study 29676972 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina air abrasion with 50‐μm alumina particles and Monobond Plus/Variolink II (Al-MB)
Number of subjects: 80
Study 29676972 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond Universal/RelyX Unicem 2 without air abrasion (SU)
Number of subjects: 80
Study 29676972 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina air abrasion with 50‐μm alumina particles and Alloy Primer/ED Primer II/Panavia F 2.0 (Al-AP)
Number of subjects: 80
Study 27261936 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine (3 mg/kg body weight)
Number of subjects: 13
Study 25029008 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 2 g/day for 28 days
Number of subjects: 41
Study 25029008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) 2 g/day for 28 days
Number of subjects: 41
Study 25029008 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 41
Study 25029008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 41
Study 22659999 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B‐12 (500 µg/day) for 12 weeks
Number of subjects: 50
Study 22659999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20689153 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-Defusion
Number of subjects: 0
Study 20689153 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-Defusion
Number of subjects: 0
Study 20689153 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-Distraction
Number of subjects: 0
Study 20689153 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-Distraction
Number of subjects: 0
Study 20689153 — intervention group
Group type: COMPARATOR
Intervention: Distraction-based experimental control task
Number of subjects: 0
Study 19021036 — intervention group
Group type: EXPERIMENTAL
Intervention: Various innovative and culturally specific interventions targeting children's lifestyle behaviors
Number of subjects: 28
Study 16171665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg/kg IV followed by continuous infusion of 0.5 mg/kg per hour until the end of surgery (group I)
Number of subjects: 40
Study 16171665 — intervention group
Group type: COMPARATOR
Intervention: IV normal saline (group II)
Number of subjects: 40
Study 12854475 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg.kg-1 propofol (group P2)
Number of subjects: 90
Study 12854475 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg.kg-1 propofol (group P1)
Number of subjects: 90
Study 12854475 — intervention group
Group type: COMPARATOR
Intervention: Intralipid 0.2 ml.kg-1 (group C)
Number of subjects: 90
Study 9884384 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 36
Study 9884384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 36
Study 9884384 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (before NG‐monomethyl‐L‐arginine)
Number of subjects: 36
Study 9884384 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (after NG‐monomethyl‐L‐arginine)
Number of subjects: 36
Study 9884384 — intervention group
Group type: COMPARATOR
Intervention: Forearm ischemia
Number of subjects: 36
Study 8559420 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 137
Study 8559420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 1651071 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 13‐cis‐retinoic acid
Number of subjects: 0
Study 1651071 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of all‐trans‐retinoic acid
Number of subjects: 0
Study 1651071 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of arotinoid methyl sulphone
Number of subjects: 0
Study 1651071 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of arotinoid ethyl sulphone
Number of subjects: 0
Study 1651071 — intervention group
Group type: COMPARATOR
Intervention: Placebo creams
Number of subjects: 0
Study 6352603 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin (group I) at mean dosage of 252 mg/kg/day for a mean duration of 13.2 days
Number of subjects: 26
Study 6352603 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin (group II) at mean dosage of 505 mg/kg/day for a median duration of 12.6 days
Number of subjects: 26
Study 6352603 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin (group I)
Number of subjects: 26
Study 6352603 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin (group II)
Number of subjects: 26
Study 31111060 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 166
Study 31111060 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 166
Study 26575606 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 10050
Study 26575606 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 10050
Study 26575606 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin use
Number of subjects: 10050
Study 26575606 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression from prediabetes to diabetes
Number of subjects: 10050
Study 26575606 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment initiation in overt diabetes
Number of subjects: 10050
Study 26575606 — intervention group
Group type: EXPERIMENTAL
Intervention: Years lived without glucose impairment
Number of subjects: 10050
Study 24283587 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-free method
Number of subjects: 93
Study 24283587 — intervention group
Group type: COMPARATOR
Intervention: Catheter-insertion method
Number of subjects: 93
Study 21691841 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepaid cash incentive ($2)
Number of subjects: 3000
Study 21691841 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 3000
Study 21691841 — intervention group
Group type: EXPERIMENTAL
Intervention: High lottery (2 prizes of $250)
Number of subjects: 3000
Study 21691841 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepaid cash
Number of subjects: 3000
Study 19638647 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate large loop excision
Number of subjects: 1983
Study 19638647 — intervention group
Group type: COMPARATOR
Intervention: Biopsy and selective recall
Number of subjects: 1983
Study 17505703 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 22
Study 17505703 — intervention group
Group type: COMPARATOR
Intervention: Chymopapain
Number of subjects: 22
Study 17505703 — intervention group
Group type: COMPARATOR
Intervention: Chemonucleolysis with chymopapain
Number of subjects: 22
Study 15342160 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic test for inversion at 120 degrees/s
Number of subjects: 11
Study 15342160 — intervention group
Group type: COMPARATOR
Intervention: Isokinetic test for eversion at 120 degrees/s
Number of subjects: 11
Study 15342160 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic test for inversion and eversion at 30 degrees/s
Number of subjects: 11
Study 12377958 — intervention group
Group type: COMPARATOR
Intervention: EPI alone (60 mg/m(2) on days 1 and 2 every 21 days)
Number of subjects: 371
Study 12377958 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI and CDDP (30 mg/m(2) on days 1 and 2 every 21 days)
Number of subjects: 371
Study 12377958 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI and LND (450 mg orally daily, given continuously)
Number of subjects: 371
Study 12377958 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI, CDDP, and LND
Number of subjects: 371
Study 9846090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 55
Study 9846090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9846090 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu‐380A and Nova T (R.)
Number of subjects: 55
Study 7863045 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB) 50-100 mg/day
Number of subjects: 54
Study 7863045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 54
Study 2768611 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral skills training program
Number of subjects: 100
Study 2768611 — intervention group
Group type: EXPERIMENTAL
Intervention: Feelings-based program
Number of subjects: 100
Study 2768611 — intervention group
Group type: COMPARATOR
Intervention: Control presentation
Number of subjects: 100
Study 821075 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered thyrotropin-releasing hormone (TRH) at a dosage of 200 to 300 mg daily
Number of subjects: 11
Study 821075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31610635 — intervention group
Group type: EXPERIMENTAL
Intervention: Female infants at 7 months of age for tetanus and filamentous haemagglutinin
Number of subjects: 398
Study 31610635 — intervention group
Group type: EXPERIMENTAL
Intervention: Female infants at 13 months of age for polio type 3, pneumococcal serotype 6A and measles
Number of subjects: 398
Study 31610635 — intervention group
Group type: COMPARATOR
Intervention: Sex influence on seroprotection rates
Number of subjects: 398
Study 31610635 — intervention group
Group type: COMPARATOR
Intervention: Delivery mode, feeding method and antibiotic exposure
Number of subjects: 398
Study 31284771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg once daily
Number of subjects: 3864
Study 31284771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg twice daily
Number of subjects: 3864
Study 31284771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg twice daily
Number of subjects: 3864
Study 31284771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3864
Study 28599630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1.8 g daily, containing 1.08 g of EPA and 0.72 g of DHA)
Number of subjects: 60
Study 28599630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 60
Study 28599630 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60